Radium Ra 223 dichloride is under clinical development by Bayer and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Radium Ra 223 dichloride’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Carcinoma took place on 28 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Radium Ra 223 dichloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Radium Ra 223 dichloride overview

Radium-223 chloride (Xofigo) is an antineoplastic agent, It is formulated as solution for intravenous route of administration. It is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

Radium-223 chloride is under development for the treatment of castration resistant prostate cancer (CRPC) with bone metastasis, non-small cell lung cancer (NSCLC) with bone metastases, metastatic renal cell carcinoma and metastatic osteosarcoma. It was also under development for the treatment of metastatic castration-resistant (hormone-refractory) prostate cancer and metastatic HER2 negative hormone receptor-positive breast cancer patients with bone metastases and multiple myeloma.

Bayer overview

Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

Quick View Radium Ra 223 dichloride LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Radium Ra 223 dichloride
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Bayer
  • Originator: Algeta
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.